Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure
Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial
Objective: Phase I study with AFFITOPE® PD01A and PD03A to assess safety and tolerability as well as immunogenicity of this approach in MSA patients. Background:…PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach
Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…Nilotinib for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of nilotinib on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)
Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…Rapamycin for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Patient Perspective in Multiple System Atrophy
Objective: To report patient and/ or caregiver perspective in Multiple System Atrophy (MSA). Background: The majority of literature on MSA’s natural history comes from single…Is safinamide useful for atypical Parkinsonian syndromes?
Objective: Seeking new treatment strategies in atypical Parkinsonian syndromes Background: Atypical parkinsonian syndromes (APS) include several entities leading to parkinsonism with atypical features such as…The role of deep brain stimulation targeting GPi in patients with multiple system atrophy
Objective: To report clinical outcomes of two patients diagnosed with MSA-P who underwent bilateral deep brain stimulation (DBS). Background: The role of DBS in patients…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »